Abstract
The matrix metalloproteinases are a family of nearly 30 enzymes that are intimately involved in tissue remodeling. Disease processes associated with the matrix metalloproteinases are generally related to imbalance between the inhibition and activation of matrix metalloproteinases resulting in excessive degradation of the extracellullar matrix. These include osteoarthritis, rheumatoid arthritis, tumor metastasis and congestive heart failure. Despite massive research and development efforts, there are only two drugs launched on the market: periostat (doxycycline), a tetracycline used for periodontal disease and glucosemine sulfate, for osteoarthritis. Possible reasons for the low success rate of matrix metalloproteinase inhibitors in the clinic are mainly from unwanted side effects caused by their lack of selectivity, since inhibition of collagenase-1 may be responsible for the musculoskeletal side effects observed clinically with broad-spectrum inhibitors. Considering these data, many efforts were directed to developing a more selective second generation of inhibitors against the specific matrix metalloproteinases believed to be involved in the different pathologies. This review mainly focuses on selective matrix metalloproteinase inhibitors development on matrix metalloproteinases in terms of antitumor since the late 90s, in terms of synthetic compounds of low molecular mass incorporating specific zinc-binding groups, natural products and their derivatives. Through these methods, new hope is emerging in the form of synthetic and natural matrix metalloproteinase inhibitors for the prevention and treatment of cancer.
Keywords: Matrix metalloproteinases, selective inhibitors, synthetic compounds, natural products, derivatives, progress, antitumor
Current Medicinal Chemistry
Title: Selective Matrix Metalloproteinase Inhibitors for Cancer
Volume: 16 Issue: 29
Author(s): Nian-Guang Li, Zhi-Hao Shi, Yu-Ping Tang and Jin-Ao Duan
Affiliation:
Keywords: Matrix metalloproteinases, selective inhibitors, synthetic compounds, natural products, derivatives, progress, antitumor
Abstract: The matrix metalloproteinases are a family of nearly 30 enzymes that are intimately involved in tissue remodeling. Disease processes associated with the matrix metalloproteinases are generally related to imbalance between the inhibition and activation of matrix metalloproteinases resulting in excessive degradation of the extracellullar matrix. These include osteoarthritis, rheumatoid arthritis, tumor metastasis and congestive heart failure. Despite massive research and development efforts, there are only two drugs launched on the market: periostat (doxycycline), a tetracycline used for periodontal disease and glucosemine sulfate, for osteoarthritis. Possible reasons for the low success rate of matrix metalloproteinase inhibitors in the clinic are mainly from unwanted side effects caused by their lack of selectivity, since inhibition of collagenase-1 may be responsible for the musculoskeletal side effects observed clinically with broad-spectrum inhibitors. Considering these data, many efforts were directed to developing a more selective second generation of inhibitors against the specific matrix metalloproteinases believed to be involved in the different pathologies. This review mainly focuses on selective matrix metalloproteinase inhibitors development on matrix metalloproteinases in terms of antitumor since the late 90s, in terms of synthetic compounds of low molecular mass incorporating specific zinc-binding groups, natural products and their derivatives. Through these methods, new hope is emerging in the form of synthetic and natural matrix metalloproteinase inhibitors for the prevention and treatment of cancer.
Export Options
About this article
Cite this article as:
Li Nian-Guang, Shi Zhi-Hao, Tang Yu-Ping and Duan Jin-Ao, Selective Matrix Metalloproteinase Inhibitors for Cancer, Current Medicinal Chemistry 2009; 16 (29) . https://dx.doi.org/10.2174/092986709789178037
DOI https://dx.doi.org/10.2174/092986709789178037 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Innate Immunity in Triggering and Tuning of Autoimmune Diabetes
Current Molecular Medicine Role of Dietary Xenobiotics-Gene Interactions in Carcinogenesis: Protective Effects of Nutritional Factors
Current Nutrition & Food Science Stairway to Heaven or Hell? Perspectives and Limitations of Chagas Disease Chemotherapy
Current Topics in Medicinal Chemistry Epigenetic control of cardiovascular health by nutritional polyphenols involves multiple chromatin-modifying writer-reader-eraser proteins
Current Topics in Medicinal Chemistry The role of NADPH Oxidase in Vascular Disease – Hypertension, Atherosclerosis & Stroke
Current Pharmaceutical Design Type 1 Diabetes Mellitus - Risk Factor for Cardiovascular Disease Morbidity and Mortality
Current Diabetes Reviews The In Silico Prediction of Human-Specific Metabolites from Hepatotoxic Drugs
Current Drug Discovery Technologies Growth Hormone Secretagogues
Combinatorial Chemistry & High Throughput Screening Cooling the Injured Brain: How Does Moderate Hypothermia Influence the Pathophysiology of Traumatic Brain Injury
Current Pharmaceutical Design Reversing Anticoagulant Therapy
Current Drug Discovery Technologies Good at Heart: Preserving Cardiac Metabolism during aging
Current Diabetes Reviews Pharmacological Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Isothiocyanates as Cancer Chemopreventive Agents: Their Biological Activities and Metabolism in Rodents and Humans
Current Drug Metabolism Natural Product-Derived Small Molecule Activators of Hypoxia-Inducible Factor-1 (HIF-1)
Current Pharmaceutical Design Crocetin as an Active Secondary Metabolite of Saffron Stigma and Anticancer Effects
Current Cancer Therapy Reviews The Developing Role of Neuregulin1 In Cardiac Regenerative Stem Cell Therapy
Current Pharmaceutical Design Is Peri-Operative Isolated Systolic Hypertension (ISH) a Cardiac Risk Factor?
Current Cardiology Reviews Transforming Growth Factor β Signaling Perturbation in the Loeys-Dietz Syndrome
Current Medicinal Chemistry Soluble Epoxide Hydrolase, a Target with Multiple Opportunities for Cardiovascular Drug Discovery
Current Topics in Medicinal Chemistry Recent Trends on the Use of Nanoparticles for Nitric Oxide Delivery in Antimicrobial Applications
Drug Delivery Letters